NO20084039L - Metoder for forebygging og behandling av amyloidogeniske sykdommer - Google Patents
Metoder for forebygging og behandling av amyloidogeniske sykdommerInfo
- Publication number
- NO20084039L NO20084039L NO20084039A NO20084039A NO20084039L NO 20084039 L NO20084039 L NO 20084039L NO 20084039 A NO20084039 A NO 20084039A NO 20084039 A NO20084039 A NO 20084039A NO 20084039 L NO20084039 L NO 20084039L
- Authority
- NO
- Norway
- Prior art keywords
- prevention
- treatment
- methods
- amyloidogenic diseases
- rage
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 102000009091 Amyloidogenic Proteins Human genes 0.000 title 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 title 1
- 230000003942 amyloidogenic effect Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 101800001718 Amyloid-beta protein Proteins 0.000 abstract 1
- 230000003941 amyloidogenesis Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
SAMMENDRAG Fremgangsmåte for behandling av en syk dom eller lidelse karakterisert ved amyloid avleiring av A-beta omfattende å administrere til individet en terapeutisk effektiv mengde av et antistoff som binder spesifikt til RAGE og hemmer bindingen av en RAGE bindingspartner.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78457506P | 2006-03-21 | 2006-03-21 | |
US89530307P | 2007-03-16 | 2007-03-16 | |
PCT/US2007/064571 WO2007109749A2 (en) | 2006-03-21 | 2007-03-21 | Methods for preventing and treating amyloidogenic diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20084039L true NO20084039L (no) | 2008-12-15 |
Family
ID=38523302
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20083720A NO20083720L (no) | 2006-03-21 | 2008-08-29 | Fremgangsmater og sammensetninger for antagonisme av RAGE |
NO20084039A NO20084039L (no) | 2006-03-21 | 2008-09-23 | Metoder for forebygging og behandling av amyloidogeniske sykdommer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20083720A NO20083720L (no) | 2006-03-21 | 2008-08-29 | Fremgangsmater og sammensetninger for antagonisme av RAGE |
Country Status (13)
Country | Link |
---|---|
US (2) | US20070286858A1 (no) |
EP (2) | EP2001907A2 (no) |
JP (2) | JP2009529920A (no) |
KR (2) | KR20080113236A (no) |
AU (2) | AU2007226863A1 (no) |
BR (2) | BRPI0708970A2 (no) |
CA (2) | CA2638755A1 (no) |
CR (2) | CR10298A (no) |
EC (1) | ECSP088750A (no) |
MX (2) | MX2008012023A (no) |
NO (2) | NO20083720L (no) |
RU (2) | RU2008134135A (no) |
WO (2) | WO2007109747A2 (no) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
US7608586B2 (en) * | 2003-06-11 | 2009-10-27 | The University Of Rochester | Soluble low-density lipoprotein receptor related protein binds directly to Alzheimer's amyloid-beta peptide |
PT1976877E (pt) | 2005-11-30 | 2014-04-29 | Abbvie Inc | Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações |
EP1954718B1 (en) | 2005-11-30 | 2014-09-03 | AbbVie Inc. | Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
CA2646329C (en) | 2006-03-20 | 2018-07-03 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
BRPI0708970A2 (pt) * | 2006-03-21 | 2011-06-21 | Wyeth Corp | método para o tratamento de um sujeito com uma doença ou transtorno caracterizado por depósito amilóide de a-beta; método de inibição ou redução da acumulação de depósito amilóide de a-beta em um sujeito; método de inibição ou redução da neurodegeneração em um sujeito; e método de inibição ou redução do declìnio cognitivo, ou de melhora da cognição, em um sujeito |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
WO2008131908A1 (en) * | 2007-04-26 | 2008-11-06 | Active Biotech Ab | S100a9 interaction screening method |
EP1986009A1 (en) * | 2007-04-26 | 2008-10-29 | Active Biotech AB | Screening method |
CA2698343C (en) | 2007-09-04 | 2018-06-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
EP2257634A1 (en) * | 2008-03-12 | 2010-12-08 | Wyeth LLC | Method for identifying cells suitable for large-scale production of recombinant proteins |
NZ588554A (en) | 2008-04-29 | 2013-03-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
SG188142A1 (en) * | 2008-05-09 | 2013-03-28 | Abbott Gmbh & Co Kg | Antibodies to receptor of advanced glycation end products (rage) and uses thereof |
JP2009276245A (ja) * | 2008-05-15 | 2009-11-26 | Shiseido Co Ltd | 持続性皮膚炎症性疾患の改善剤をスクリーニングする方法及びその改善剤 |
AR072001A1 (es) | 2008-06-03 | 2010-07-28 | Abbott Lab | Inmunoglobulina con dominio variable dual y usos de la misma |
CN102112494A (zh) * | 2008-06-03 | 2011-06-29 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
WO2010006060A2 (en) | 2008-07-08 | 2010-01-14 | Abbott Laboratories | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
CA2731617A1 (en) * | 2008-07-22 | 2010-01-28 | Maria Joao Saraiva | Amino acid sequences directed against multitarget scavenger receptors and polypeptides |
WO2010019656A1 (en) * | 2008-08-12 | 2010-02-18 | Wyeth | Humanized anti-rage antibody |
WO2010036856A2 (en) * | 2008-09-26 | 2010-04-01 | Wyeth Llc | Compatible display vector systems |
CA2737752A1 (en) * | 2008-09-26 | 2010-04-01 | Wyeth Llc | Compatible display vector systems |
MX2011007624A (es) * | 2009-01-19 | 2011-10-12 | Hospices Civils Lyon | Metodos para determinar la susceptibilidad de contraer una infeccion nosocomial en el paciente y para establecer el pronostico de la evolucion del sindrome septico. |
ES2712732T3 (es) | 2009-02-17 | 2019-05-14 | Cornell Res Foundation Inc | Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico |
CN102803292A (zh) * | 2009-04-20 | 2012-11-28 | 辉瑞公司 | 蛋白质糖基化的控制及其相关组合物和方法 |
EP2473524A4 (en) * | 2009-09-01 | 2013-05-22 | Abbott Lab | IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE |
BR112012007821A2 (pt) * | 2009-10-09 | 2017-05-30 | Sanofi Sa | polipeptídeos para ligação ao "receptor de produtos finais de glicação avançada" bem como composições e métodos envolvendo os mesmos |
EP2319871A1 (en) * | 2009-11-05 | 2011-05-11 | Sanofi-aventis | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
EP2308896A1 (en) * | 2009-10-09 | 2011-04-13 | Sanofi-aventis | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
EP2488658A4 (en) | 2009-10-15 | 2013-06-19 | Abbvie Inc | IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
WO2011053707A1 (en) | 2009-10-31 | 2011-05-05 | Abbott Laboratories | Antibodies to receptor for advanced glycation end products (rage) and uses thereof |
MX354143B (es) | 2009-12-02 | 2018-02-14 | Imaginab Inc | Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antígeno de membrana específico para próstata de humano (psma) y métodos para su uso. |
JP2013523182A (ja) | 2010-04-15 | 2013-06-17 | アボット・ラボラトリーズ | アミロイドベータ結合タンパク質 |
EP3252072A3 (en) | 2010-08-03 | 2018-03-14 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
EP2603524A1 (en) | 2010-08-14 | 2013-06-19 | AbbVie Inc. | Amyloid-beta binding proteins |
KR20130139884A (ko) | 2010-08-26 | 2013-12-23 | 애브비 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
EP3604339B1 (en) | 2011-01-14 | 2021-03-10 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
CA2825589A1 (en) * | 2011-01-25 | 2012-08-02 | George A. Luiken | Method for combined imaging and treating organs and tissues |
CN103460045B (zh) | 2011-04-05 | 2016-01-20 | 奥林巴斯株式会社 | 胰脏检查方法及胰脏检查试剂盒 |
US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
US9561274B2 (en) | 2011-06-07 | 2017-02-07 | University Of Hawaii | Treatment and prevention of cancer with HMGB1 antagonists |
CN104159920A (zh) | 2011-12-30 | 2014-11-19 | 艾伯维公司 | 针对il-13和/或il-17的双重可变结构域免疫球蛋白 |
KR101477130B1 (ko) | 2012-01-11 | 2015-01-06 | 연세대학교 산학협력단 | 용해성 rage를 유효성분으로 포함하는 심근염의 예방 또는 치료용 약제학적 조성물 |
US9803005B2 (en) | 2012-05-24 | 2017-10-31 | Alexion Pharmaceuticals, Inc. | Humaneered anti-factor B antibody |
KR20180008921A (ko) | 2012-11-01 | 2018-01-24 | 애브비 인코포레이티드 | 항-vegf/dll4 이원 가변 도메인 면역글로불린 및 이의 용도 |
CN105324396A (zh) | 2013-03-15 | 2016-02-10 | 艾伯维公司 | 针对IL-1β和/或IL-17的双重特异性结合蛋白 |
IL293871A (en) | 2013-08-30 | 2022-08-01 | Immunogen Inc | Antibodies and assays for the detection of folate receptor 1 |
CA2929077A1 (en) * | 2013-10-31 | 2015-05-07 | Amgen Inc. | Use of monensin to regulate glycosylation of recombinant proteins |
EP3077823B1 (en) | 2013-12-05 | 2019-09-04 | The Broad Institute, Inc. | Compositions and methods for identifying and treating cachexia or pre-cachexia |
WO2015161311A2 (en) * | 2014-04-18 | 2015-10-22 | The Research Foundation For The State University Of New York | Humanized anti-tf-antigen antibodies |
US10023651B2 (en) | 2014-04-18 | 2018-07-17 | The Research Foundation For The State University Of New York | Humanized anti-TF-antigen antibodies |
WO2016061532A1 (en) * | 2014-10-16 | 2016-04-21 | The Broad Institute Inc. | Compositions and methods for identifying and treating cachexia or pre-cachexia |
JP6679096B2 (ja) * | 2014-10-21 | 2020-04-15 | 学校法人 久留米大学 | Rageアプタマーおよびその用途 |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
WO2016201319A1 (en) * | 2015-06-10 | 2016-12-15 | The Broad Institute Inc. | Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia |
EP3307785A4 (en) * | 2015-06-10 | 2018-12-05 | Stemcell Technologies Inc. | Method for the in situ formation of bifunctional immunological complexes |
EP3307781B8 (en) | 2015-06-10 | 2020-12-02 | The Broad Institute, Inc. | Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
EP4137158A1 (en) | 2015-08-07 | 2023-02-22 | Imaginab, Inc. | Antigen binding constructs to target molecules |
JP6880006B2 (ja) | 2015-09-17 | 2021-06-02 | イミュノジェン, インコーポレイテッド | 抗folr1免疫複合体を含む治療組み合わせ |
US11111296B2 (en) | 2015-12-14 | 2021-09-07 | The Broad Institute, Inc. | Compositions and methods for treating cardiac dysfunction |
US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
KR20190134997A (ko) | 2017-02-17 | 2019-12-05 | 데날리 테라퓨틱스 인크. | 항-tau 항체 및 이의 사용 방법 |
WO2020019095A1 (es) * | 2018-07-26 | 2020-01-30 | Universidad Católica Del Maule | Proteína rage (receptor de productos finales de glicacíon avanzada) como biomarcador de sensibilidad tumoral y evaluacion de terapia radiologica y radiomimética |
US11621087B2 (en) * | 2019-09-24 | 2023-04-04 | International Business Machines Corporation | Machine learning for amyloid and tau pathology prediction |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196265A (en) * | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US6054561A (en) * | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US6893625B1 (en) * | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
US5041138A (en) * | 1986-11-20 | 1991-08-20 | Massachusetts Institute Of Technology | Neomorphogenesis of cartilage in vivo from cell culture |
EP0307434B2 (en) * | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5132405A (en) * | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5892019A (en) * | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
KR0162259B1 (ko) * | 1989-12-05 | 1998-12-01 | 아미 펙터 | 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체 |
US6300129B1 (en) * | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
GB9115364D0 (en) * | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
US5625048A (en) * | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
US5777079A (en) * | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
US5871902A (en) * | 1994-12-09 | 1999-02-16 | The Gene Pool, Inc. | Sequence-specific detection of nucleic acid hybrids using a DNA-binding molecule or assembly capable of discriminating perfect hybrids from non-perfect hybrids |
US5739277A (en) * | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
WO1997026913A1 (en) * | 1996-01-26 | 1997-07-31 | The Trustees Of Columbia University In The City Of New York | A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE |
US5864018A (en) * | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
US6124128A (en) * | 1996-08-16 | 2000-09-26 | The Regents Of The University Of California | Long wavelength engineered fluorescent proteins |
ATE364718T1 (de) * | 1997-04-01 | 2007-07-15 | Solexa Ltd | Verfahren zur vervielfältigung von nukleinsäure |
AU6766800A (en) * | 1999-08-13 | 2001-03-13 | Trustees Of Columbia University In The City Of New York, The | Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof |
CN1468250A (zh) * | 2000-08-03 | 2004-01-14 | ��ķһ����˹��̹ | 在转基因动物中产生人源化抗体 |
US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
JP4171228B2 (ja) * | 2001-03-19 | 2008-10-22 | 第一ファインケミカル株式会社 | 可溶型rage測定法 |
US20040058445A1 (en) * | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
US7321026B2 (en) * | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
CN1774445A (zh) * | 2002-08-16 | 2006-05-17 | 惠氏公司 | 用于治疗rage相关病症的组合物和方法 |
DE10244202A1 (de) * | 2002-09-23 | 2004-03-25 | Alstom (Switzerland) Ltd. | Elektrische Maschine mit einem Stator mit gekühlten Wicklungsstäben |
JP4914209B2 (ja) * | 2003-03-14 | 2012-04-11 | ワイス | ヒトil−21受容体に対する抗体および該抗体の使用 |
EP2272566A3 (en) * | 2003-08-18 | 2013-01-02 | MedImmune, LLC | Humanisation of antibodies |
US20070014791A1 (en) * | 2003-09-05 | 2007-01-18 | Schmidt Ann M | Rage-related methods and copositions for treating glomerular injury |
KR100570422B1 (ko) * | 2003-10-16 | 2006-04-11 | 한미약품 주식회사 | 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법 |
BRPI0708970A2 (pt) * | 2006-03-21 | 2011-06-21 | Wyeth Corp | método para o tratamento de um sujeito com uma doença ou transtorno caracterizado por depósito amilóide de a-beta; método de inibição ou redução da acumulação de depósito amilóide de a-beta em um sujeito; método de inibição ou redução da neurodegeneração em um sujeito; e método de inibição ou redução do declìnio cognitivo, ou de melhora da cognição, em um sujeito |
-
2007
- 2007-03-21 BR BRPI0708970-8A patent/BRPI0708970A2/pt not_active IP Right Cessation
- 2007-03-21 JP JP2009501725A patent/JP2009529920A/ja active Pending
- 2007-03-21 AU AU2007226863A patent/AU2007226863A1/en not_active Abandoned
- 2007-03-21 WO PCT/US2007/064568 patent/WO2007109747A2/en active Application Filing
- 2007-03-21 RU RU2008134135/13A patent/RU2008134135A/ru not_active Application Discontinuation
- 2007-03-21 CA CA002638755A patent/CA2638755A1/en not_active Abandoned
- 2007-03-21 BR BRPI0708998-8A patent/BRPI0708998A2/pt not_active IP Right Cessation
- 2007-03-21 KR KR1020087025056A patent/KR20080113236A/ko not_active Application Discontinuation
- 2007-03-21 MX MX2008012023A patent/MX2008012023A/es not_active Application Discontinuation
- 2007-03-21 KR KR1020087025473A patent/KR20080110833A/ko not_active Application Discontinuation
- 2007-03-21 WO PCT/US2007/064571 patent/WO2007109749A2/en active Application Filing
- 2007-03-21 RU RU2008137764/13A patent/RU2008137764A/ru not_active Application Discontinuation
- 2007-03-21 US US11/689,480 patent/US20070286858A1/en not_active Abandoned
- 2007-03-21 JP JP2009501727A patent/JP2009530423A/ja not_active Withdrawn
- 2007-03-21 CA CA002646643A patent/CA2646643A1/en not_active Abandoned
- 2007-03-21 AU AU2007226861A patent/AU2007226861A1/en not_active Abandoned
- 2007-03-21 US US11/689,501 patent/US20070253950A1/en not_active Abandoned
- 2007-03-21 EP EP07759057A patent/EP2001907A2/en not_active Withdrawn
- 2007-03-21 EP EP07759060A patent/EP2004694A2/en not_active Withdrawn
- 2007-03-21 MX MX2008011933A patent/MX2008011933A/es unknown
-
2008
- 2008-08-29 NO NO20083720A patent/NO20083720L/no not_active Application Discontinuation
- 2008-09-19 EC EC2008008750A patent/ECSP088750A/es unknown
- 2008-09-19 CR CR10298A patent/CR10298A/es not_active Application Discontinuation
- 2008-09-19 CR CR10297A patent/CR10297A/es not_active Application Discontinuation
- 2008-09-23 NO NO20084039A patent/NO20084039L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CR10297A (es) | 2008-12-02 |
WO2007109749A2 (en) | 2007-09-27 |
BRPI0708998A2 (pt) | 2011-06-21 |
MX2008012023A (es) | 2008-10-01 |
CA2646643A1 (en) | 2007-09-27 |
WO2007109747A2 (en) | 2007-09-27 |
AU2007226863A1 (en) | 2007-09-27 |
BRPI0708970A2 (pt) | 2011-06-21 |
CA2638755A1 (en) | 2007-09-27 |
JP2009529920A (ja) | 2009-08-27 |
CR10298A (es) | 2008-11-18 |
KR20080110833A (ko) | 2008-12-19 |
KR20080113236A (ko) | 2008-12-29 |
MX2008011933A (es) | 2008-12-18 |
EP2001907A2 (en) | 2008-12-17 |
US20070286858A1 (en) | 2007-12-13 |
JP2009530423A (ja) | 2009-08-27 |
ECSP088750A (es) | 2008-10-31 |
WO2007109747A3 (en) | 2008-05-22 |
WO2007109749A8 (en) | 2009-06-18 |
RU2008134135A (ru) | 2010-04-27 |
US20070253950A1 (en) | 2007-11-01 |
EP2004694A2 (en) | 2008-12-24 |
AU2007226861A1 (en) | 2007-09-27 |
WO2007109749A3 (en) | 2008-03-06 |
NO20083720L (no) | 2008-12-12 |
RU2008137764A (ru) | 2010-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20084039L (no) | Metoder for forebygging og behandling av amyloidogeniske sykdommer | |
NO20084650L (no) | Modifiserte humaniserte anti-interleukin-18 antistoffer | |
NO20091635L (no) | Sammensetninger og fremgangsmater for diagnostisering og behandling av kreft | |
EA200801842A1 (ru) | Антитела против бета-амилоидного пептида | |
EA201690111A1 (ru) | Имидазопиразиновые ингибиторы тирозинкиназы syk | |
EA201190043A1 (ru) | Имидазопиразиновые ингибиторы syk | |
NO20065252L (no) | Behandling av forstyrrelser | |
WO2008025020A3 (en) | Cd30 binding agents and uses thereof | |
EA200870385A1 (ru) | Ингибирование токсичности альфа-синуклеина | |
BRPI0908276B8 (pt) | uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite | |
WO2007019153A3 (en) | Methods for treating hypertension | |
WO2010005566A3 (en) | Notch-binding agents and antagonists and methods of use thereof | |
EA200970317A1 (ru) | Комбинированное лечение опухолей, экспрессирующих cd38 | |
NO20080302L (no) | Humane anti-B7RP1 noytraliserende antistoffer | |
EA201170716A1 (ru) | Антитела к с-мет | |
BRPI0907135B8 (pt) | uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica | |
BRPI0906094B8 (pt) | composto | |
WO2009153665A3 (en) | Inhibitors of the shiga toxins trafficking through the retrograde pathway | |
EA200900831A1 (ru) | Модуляторы никотиновых ацетилхолиновых рецепторов | |
NO20082894L (no) | Metode for behandling av kognitiv dysfunksjon | |
EA201001496A1 (ru) | Ингибиторы гранулоцитарно-макрофагального колониестимулирующего фактора (gm-csf) и интерлейкина-17 (il-17) для терапии | |
WO2008100563A3 (en) | Compositions and methods for diagnosing and treating cancer | |
AR107893A1 (es) | TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE | |
MX2011012666A (es) | Usos de anticuerpos il-1beta y sus fragmentos de union relacionados con eventos cardiovasculares. | |
WO2007101148A3 (en) | Hexose compounds to treat cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |